Included in the classification of coronary heart
|
|
- Willa Gardner
- 5 years ago
- Views:
Transcription
1 IN SEARCH OF CARDIOPROTECTION: A OF POTENTIAL AGENTS William C. Stanley, PhD* ABSTRACT Coronary heart disease (CHD) is the leading cause of death of men and women in the United States and it consumes a hefty portion of healthcare expenditures. Optimal treatment of CHD should be individualized based upon concurrent medications and medical conditions and may include lifestyle changes, and pharmacological and/or surgical therapy. Traditional pharmacologic approaches for treating ischemic heart disease have either increased oxygen supply to the heart muscle or decreased oxygen demand of the muscle by increasing coronary blood flow and reducing heart rate, cardiac contractility, arterial blood pressure, and afterload on the left ventricle. The organic nitrates are effective antianginal therapy; however, their long-term use is associated with tolerance issues. Calcium-channel blockers are safe and well-tolerated agents useful in patients with effort angina, particularly in those with concurrent hypertension. Data suggest that short-acting dihydropyridines should not be used in CHD patients. Beta blockers are considered treatment of choice in the management of CHD in the postinfarct and overt heart failure settings. Hypotheses supporting the anti-ischemic properties of angiotensin-converting enzyme inhibitors are reviewed. Novel therapies decrease anginal symptoms via modulation of myocardial energy substrate metabolism and include carnitine derivatives, antioxidants, and direct inhibitors of fatty acid beta-oxidation. The efficacy and tolerability *Associate Professor, Department of Physiology and Biophysics, Case Western Reserve University, School of Medicine, Cleveland, Ohio. Address correspondence to: William C. Stanley, PhD, Case Western Reserve University, Euclid Avenue, Cleveland, OH wcs4@cwru.edu. of fatty acid oxidation inhibitors, trimetazidine and ranolazine, have been demonstrated in controlled clinical trials. These novel agents may prove to be particularly useful in patients on maximal dosages of traditional agents, for those who cannot tolerate hemodynamic-based therapy, or are not candidates for revascularization. New agents utilizing the nonhemodynamic mechanism of action for the management of angina offer promise in controlling the frequency of anginal attacks and improving exercise tolerance in CHD patients. (Adv Stud Med. 2004;4(6B):S472-S478) Included in the classification of coronary heart disease (CHD) are acute myocardial ischemia and acute coronary syndrome, which describes the condition of patients with acute myocardial infarction or unstable angina. CHD affects 6.4% of the US population and carries a substantial socioeconomic impact. 1 Angina affects about 6.8 million Americans (3.5% of the US population), and stable angina affects Americans. Accounting for 54% of the more than deaths per year due to cardiovascular disease (CVD), CHD is the single largest killer of American males and females (Figure 1). 1 In 2004, CHD is projected to cost $133.2 billion. Treatment of CHD may include lifestyle changes, pharmacologic therapy, and/or surgical therapy. 2 Efforts aimed at improving the prognosis of patients with CHD are evidenced by the growing incidence of cardiac revascularization procedures over the past 2 decades. 1,3 However, up to one fourth (26%) of patients 1 year postrevascularization still experience anginal attacks, including patients who receive S472 Vol. 4 (6B) June 2004
2 antianginal pharmacotherapy. 4,5 Therefore, further efforts directed toward improvement in the management of CHD are clinically meaningful. Traditionally, pharmacologic approaches for treating ischemic heart disease have either increased the oxygen supply to the heart muscle or decreased the oxygen demand of the muscle. 6 These agents work by increasing coronary blood flow and reducing heart rate, cardiac contractility, arterial blood pressure, and afterload on the left ventricle. 7 Novel therapies utilizing a different mechanism of action decrease anginal symptoms via optimization of myocardial energy metabolism. This paper reviews the rationale for pharmacologic agents, both traditional hemodynamic and novel metabolic agents, used in the treatment of myocardial ischemia. CARDIAC METABOLISM IN ISCHEMIA AND THERAPEUTIC IMPLICATIONS The healthy well-oxygenated heart derives energy, namely adenosine triphosphate (ATP), from 2 types of fuel: fatty acids (about two thirds of total) and carbohydrate (in the form of glucose and lactate). 8 Lipid oxidation inhibits the oxidation of glucose and lactate in the myocardium, and pharmacologic inhibition of cardiac fatty acid oxidation results in a rapid increase in the oxidation of glucose and lactate. The healthy heart is built for stress and increases myocardial oxygen uptake and the oxidation of fatty acids, glucose, and lactate as needed to support the work demand. Patients with CHD frequently are unable to increase myocardial blood flow to meet the tissue requirement for oxygen, thus resulting in demand-induced ischemia and impairment of the aerobic formation of ATP. This impairment results in activation of nonoxidative glycolysis and a change from myocardial uptake of lactate to production of lactate. The decrease in ATP and increase in lactate disrupts the cellular homeostasis by producing an acidic intracellular environment that contributes to contractile dysfunction in the ischemic myocardium. 7,9 Traditional hemodynamic-based antianginal agents provide relief from anginal attacks via a reduction in ATP requirements by decreasing heart rate, cardiac contractility, and/or afterload or by increasing the aerobic formation of ATP by increasing coronary blood flow. 10 An alternative novel mechanism for alleviation of anginal symptoms is to alter the metabolism of the ischemic heart. The stressed heart consumes fatty acids as fuel; this inhibits the oxidation of glucose and stimulates lactate production. In addition, fatty acids are less oxygen efficient than glucose, and the heart produces more ATP per unit of oxygen consumed using glucose compared to fatty acids. Inhibition of fatty acid oxidation works to shift the metabolism of the heart to use more glucose and fewer fatty acids during stress. This shift results in a greater ratio of ATP synthesis to oxygen consumption, a reduction in lactate production, normalization of intracellular ph, and sequential improvement in symptoms for the stable angina patient. OF TRADITIONAL THERAPIES NITROGLYCERIN The efficacy of nitroglycerin in relieving angina and preventing subsequent attacks was reported over 100 years ago, and today, nitroglycerin is the most frequently prescribed medication for treating anginal attacks. 11 The organic nitrates are prodrugs that liberate nitric oxide (NO) upon biotransformation. NO has been shown to reduce blood pressure and afterload during ischemia and acts in a similar manner to beta Figure 1. Percentage Breakdown of Deaths from Cardiovascular Disease Coronary heart disease includes myocardial infarction, angina pectoris, or both. Cardiovascular disease resulted in deaths in Reproduced with permission from the American Heart Association. Heart Disease and Stroke Statistics Update , American Heart Association. 1 Advanced Studies in Medicine S473
3 blockers and calcium antagonists by unloading the ventricle. NO also reduces platelet adhesion and aggregation and is involved in the control of endothelial function and vascular growth. Available in an array of formulations allowing for individualization of treatment strategies, nitrates are used to treat an ongoing anginal attack and to provide prophylaxis of angina. 11 Although logic dictates that nitrates plus a negative chronotropic agent would improve efficacy, limited data support the combination of nitrates with other antianginal medications. Therefore, monotherapy should be maximized prior to the addition of other agents. 11 Long-term administration of nitrates is associated with a loss of hemodynamic and antianginal effects. 11 The exact mechanism of nitrate tolerance has not been fully elucidated but evidence suggests that the 4 following events may play a role: depletion of reduced sulfhydryl groups necessary for biotransformation of nitrates, release of vasoconstrictor hormones with nitrate administration, expansion of plasma volume, and increased free-radical production by the endothelium. Although superior to continuous therapy in controlling anginal attacks, intermittent therapy with nitrates is not without complication and is associated with rebound myocardial ischemia during nitrate-free periods. CALCIUM-CHANNEL BLOCKERS Three distinct structural classes represent the calcium-channel blockers that block calcium entry into the myocardial and smooth-muscle cells resulting in relaxation of musculature and dilation of vasculature (Table 1). 12,13 All of the calciumchannel blockers, regardless of class, have demonstrated efficacy in the reduction of silent and overt ischemia. These agents reduce myocardial oxygen demand by slowing the heart rate, decreasing contractility, and reducing afterload. Additionally, oxygen delivery is improved by the dilation of coronary arteries. Due to effects on contractility, caution is advised when prescribing negative inotropic agents, including calcium-channel blockers, in patients with impaired left ventricular function. 12 Members of the dihydropyridine class appear less likely to have this effect than other calcium-channel blockers and are therefore safer in such patients. The safety of calcium-channel blockers in patients with CHD is controversial and has been debated extensively. Review of these analyses suggests that short-acting dihydropyridines should not be used in CHD patients. Overall, the calcium-channel blockers are safe and well-tolerated agents that are useful in patients with effort angina, particularly in those with concurrent hypertension. 14 BETA BLOCKERS Beta blockers have demonstrated efficacy in reducing the frequency of ischemic episodes and the rate of cardiac events in patients with stable ischemia. 12 Beta blockers reduce myocardial oxygen demand by inhibition of receptors on the myocardium that decrease the heart rate and force of contraction. Beta blockers should be considered the first treatment of choice in the management of CHD patients with chronic stable effort angina in the postinfarct and overt heart failure settings. 3,14 Some beta blockers are cardioselective, such as acebutolol, atenolol, betaxolol, carvedilol, and metoprolol and mainly block beta 1 cardiac receptors; however, all beta blockers become nonselective at higher dosages, making them generally contraindicated in patients with asthma. 12 Safety concerns with beta-blocker therapy, such as bronchospasm, impotence, and impairment of exercise ability, make the individualization of antianginal pharmacotherapy important. 14,15 Table 1. Physiologic Effects of Calcium-channel Blockers Calcium-Channel Heart Rate Myocardial Cardiac Peripheral Blocker Contractility Output/ Vascular Index Resistance Diphenylalkylamines Verapamil ± ll ± ll Benzothiazepines Diltiazem 0-l 0-l 0-j ll(dose related) Dihydropyridines Amlodipine ± 0-l j ll Felodipine jj 0-l No data ll(dose related) Isradipine j l j ll Nicardipine jj 0-l jj lll Nifedipine 0-j 0-l j lll Nisoldipine No data 0-l No data ll(dose related) jor l= pronounced effect; jor l= moderate effect; jor l= slight effect; ± = negligible. Data from Killion. 13 S474 Vol. 4 (6B) June 2004
4 ANGIOTENSIN-CONVERTING ENZYME INHIBITORS It has been suggested that angiotensin-converting enzyme (ACE) inhibitors have general cardiovascular protective benefits. The antihypertensive effects of these agents is well established, and these agents are now used in a variety of cardiovascular disorders, including heart failure. 16,17 A link to the fibrinolytic system and the implication of the renin-angiotensin system s involvement in the pathogenesis of atherosclerotic coronary artery disease (CAD) has provided theoretical evidence that ACE inhibitors provide beneficial effects on vascular wall damage. Clinical evidence coupled with epidemiologic and genetic links have supported a potential role for ACE inhibitors in reducing the risk for ischemic events in a wide range of high-risk patients. The exact mechanisms of antiatherogenic activity of ACE inhibitors is not fully understood, but a variety of hypotheses have been proposed (Table 2). The reduction in acute ischemic events with ACE inhibitors follows a 6- to 12-month time lag and suggests that the anti-ischemic activity of these agents is independent of the antihypertensive effects. Further study is ongoing to determine if the antiischemic effects of ACE inhibitors observed in highrisk patients can be transferred to a population at lower risk for events. Additionally, investigations into the anti-ischemic properties of angiotensin receptor blockers are ongoing and may provide important treatment alternatives for patients unable to tolerate side effects of ACE inhibitors, such as cough. OF NOVEL METABOLIC THERAPIES ANTIOXIDANTS Antiatherosclerosis benefits of antioxidant therapy, such as with vitamins C and E, are plausible, yet their efficacy in reducing CVD remains unproven. 12,18 Theoretical support for the efficacy of these agents is based on the antioxidant s ability to inhibit the conversion of low-density lipoprotein (LDL) to oxidized LDL or to impede the actions of oxidized LDL, which has an underlying role in the formation and rupture of atherosclerotic plaque formation. 12,18,19 Antioxidants have anti-inflammatory properties and may act to reduce the formation of plaques and improve stabilization of plaques. Also, antioxidants may relieve oxidant stress in the systemic arteries associated with endothelial dysfunction and angina. 20 The benefits of antioxidants in CVD have been suggested in several large observational studies conducted in healthy men and women receiving high doses of vitamin E. 12,19 However, the utility of vitamins C and E in CAD remains inconclusive as results of clinical studies have failed to confirm the beneficial effects of antioxidant supplementation on CAD. 12,19,21 It has been suggested that these studies were limited by the dose and type of vitamin E administered and that future study should include the more potent antioxidant vitamin E, alpha-tocotrienol vitamin E, to address the issue of this antioxidant s utility in CAD. FATTY ACID OXIDATION INHIBITORS In an effort to optimize the energy metabolism of the ischemic heart, the inhibition of fatty acid oxidation has been studied as a novel method for intervention. 6,8 During ischemic conditions, high rates of fatty acid oxidation cause a marked decrease in glucose oxidation. The inhibition of fatty acid oxidation allows for a metabolic shift to an increase in glucose oxidation, less lactate production, and a more optimal intracellular ph during demand-induced ischemia. In addition, the myocardium derives more ATP per unit of oxygen consumed from glucose oxidation than from fatty acid oxidation. Partial inhibition of myocardial fatty acid Table 2. Potential Mechanisms of Protective Effects of Angiotensin-converting Enzyme Inhibition on Ischemic Events Improvement of endothelial function Inhibition of the breakdown of bradykinin Release of nitric oxide and prostacyclin Inhibition of vascular muscle cell growth and proliferation Decrease of macrophage migration and function Inhibition of low-density lipoprotein oxidation Enhancement of endogenous fibrinolysis Inhibition of plasminogen activator inhibitor type 1 Increase of tissue-type plasminogen activator Inhibition of platelet aggregation Inhibition of sympathetic activity Reduction of blood pressure Reduction of left ventricular mass Reprinted with permission from Ambrosioni et al. Anti-ischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective. J Cardiovasc Pharmacol. 2001;37(suppl 1):S3-S9. 16 Advanced Studies in Medicine S475
5 oxidation during ischemia improved contractile function in preclinical studies and has been shown to reduce the symptoms of angina in CHD patients. CARNITINE PALMITYL TRANSFERASE I INHIBITORS Carnitine palmityl transferase I (CPT I) inhibitors drive a metabolic switch from fatty acid oxidation to glucose oxidation in the ischemic state by inhibiting fatty acid uptake by the mitochondria. 7 CPT I inhibitors, oxfenicine and perhexiline, are associated with antiischemic efficacy and subsequent improvement of cardiac functioning; however, their long-term use is confounded by cardiac hypertrophy in animal studies. In addition, high serum concentrations of perhexiline are associated with neuropathy and hepatotoxicity. 8 CARNITINE DERIVATIVES L-carnitine plays an important role in cardiac metabolism. 7 The oxidation of fatty acids requires the translocation of fatty acids into the inner mitochondrial space via transport mediated by L-carnitine. In addition, L-carnitine assists in the regulation of pyruvate oxidation. The administration of L-carnitine or propionyl L-carnitine, an L-carnitine analog, results in an increase in the oxidation of glucose. Preclinical and clinical studies have demonstrated the anti-ischemic cardioprotective benefits of L-carnitine and propionyl L-carnitine. In small studies involving patients with CAD, both agents have demonstrated a reduction in ST segment depression and left ventricular end-diastolic pressure during stress testing. 7 DIRECT FATTY ACID BETA-OXIDATION INHIBITORS Direct fatty acid beta-oxidation inhibitors include trimetazidine and ranolazine. 6 Trimetazidine. Trimetazidine is an antianginal drug that is widely used outside of North America. It is an inhibitor of the fatty acid beta-oxidation enzyme longchain 3-ketoacyl-CoA thiolase. Double-blind placebocontrolled trials in chronic stable angina demonstrated that trimetazidine monotherapy (20 mg 3 times daily) was associated with reduced frequency of angina episodes, reduced need for nitroglycerin, and improved exercise time to onset of angina or time to 1- mm ST segment depression. 8 Beneficial effects were independent of hemodynamic effects (fall in blood pressure or bradycardia). Therefore, clinical improvement associated with trimetazidine was due to direct effects on the myocardium rather than a reduction in myocardial oxygen demand. Additionally, the combination of trimetazidine and traditional antianginal therapy with beta blockers or calcium-channel blockers demonstrated beneficial effects. Overall, trimetazidine has been shown to be well tolerated and safe. Ranolazine. Antianginal efficacy of ranolazine has been demonstrated in patients with chronic stable angina, and, similar to trimetazidine, this clinical benefit was independent of direct hemodynamic effects. 8,22,23 The efficacy of sustained-release ranolazine has been demonstrated in 2 randomized, doubleblind, placebo-controlled studies. In the Monotherapy Assessment of Ranolazine in Stable Angina (MARISA) study, ranolazine monotherapy (500, 1000, or 1500 mg twice daily) in patients with angina demonstrated significant increases in exercise duration, time to onset of angina, and time to 1-mm ST segment depression at peak and trough compared to placebo. 8,22 An increased incidence of Figure 2. Frequency of Angina and Nitroglycerin Consumption in the CARISA Study CARISA = Combination Assessment of Ranolazine in Stable Angina study. Reprinted with permission from Chaitman et al, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized trial. JAMA. 2004;291(3): S476 Vol. 4 (6B) June 2004
6 dizziness, nausea, asthenia, and constipation was observed with ranolazine, mostly at the 1500-mg dose level, compared with placebo. The efficacy of ranolazine combined with traditional antianginal therapy was recently demonstrated in the Combination Assessment of Ranolazine in Stable Angina (CARISA) study. 23 Patients with chronic angina who experienced angina and ischemia while on atenolol, amlodipine, or diltiazem were randomized to receive ranolazine (750 or 1000 mg twice daily) or matching placebo. The addition of ranolazine to standard antianginal therapy was associated with an increase in exercise capacity and additional relief from angina compared to placebo (Figure 2). 23 At the completion of the double-blind portion of the CARISA study, patients were allowed to enroll in an open-label extension study in order to obtain long-term follow-up information. With a 1-year survival rate of 98.4% and a 2-year rate of 95.9%, no evidence of long-term survival consequences have been observed with ranolazine therapy in a population of patients with severe chronic angina. CONCLUSIONS Traditional antianginal therapies provide successful treatment by either increasing coronary blood flow or by reducing the consumption of oxygen by lowering the workload of the heart. 15 Although minimizing the number of medications prescribed for the management of angina is ideal, about 50% of stable angina patients who are taking optimal dosages of traditional therapy continue to experience further angina episodes. 8,24 Data supporting or refuting the efficacy of combining traditional antianginal therapies has been published. Some studies have demonstrated benefit of combining traditional agents, 25,26 whereas others reported no benefit from adding a calcium-channel blocker to beta-blocker therapy Novel metabolic therapies for the treatment of chronic stable angina offer advantages over traditional therapies in that they potentially increase the mechanical efficiency of the left ventricle but do not adversely affect hemodynamics. 7 The institution of a fatty acid oxidation inhibitors, such as ranolazine and trimetazidine, may prove to be particularly useful in patients on maximal dosages of traditional agents or for those who cannot tolerate hemodynamic-based therapy. In addition, ranolazine and trimetazidine provide an effective and safe treatment alternative for CHD patients who are not candidates for revascularization. 32 New agents utilizing a nonhemodynamic mechanism of action for the management of angina offer promise in controlling the frequency of anginal attacks in CHD patients. Individualization of therapy is important and should take into account the patient s concurrent medications and medical conditions. REFERENCES 1. American Heart Association. Heart Disease and Stroke Statistics 2004 Update. Dallas, Tex: American Heart Association; Staniforth AD. Contemporary management of chronic stable angina. Drugs Aging. 2001;18(2): Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 2003;107(1): Serruys PW, Unger F, Sousa JE, et al. for the Arterial Revascularization Therapies Study Group. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001; 344(15): Holubkov R, Laskey WK, Haviland A, et al. for the Registry Investigators. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144(5): Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis. 2001;12(suppl 1):S8-S Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33(2): Stanley WC. Partial fatty acid oxidation inhibitors for stable angina. Expert Opin Investig Drugs. 2002;11(5): Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis. 2001;12(suppl 1):S3-S Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol. 2003;17(2): Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338(8): Zanger DR, Solomon AJ, Gersh BJ. Contemporary management of angina: part II. Medical management of chronic stable angina. Am Fam Physician. 2000;61(1): Killion KH. Drug Facts and Comparisons. St Louis, Mo: Wolters Kluwer Health, Inc. Publishers; Opie LH. First line drugs in chronic stable effort angina the case for newer, longer-acting calcium channel blocking agents. J Am Coll Cardiol. 2000;36(6): Advanced Studies in Medicine S477
7 15. Singh BN. Classes of antianginal compounds: old and new therapeutic implications. J Cardiovasc Pharmacol Ther. 2003;8(2): Ambrosioni E, Bacchelli S, Esposti DD, Borghi C. Antiischemic effects of angiotensin-converting enzyme inhibitors: a future therapeutic perspective. J Cardiovasc Pharmacol. 2001;37(suppl 1):S3-S Solomon SD. Beyond remodelling: a new paradigm for angiotensin-converting enzyme inhibitors following myocardial infarction. J Cardiovasc Pharmacol. 2001;37(suppl 1):S31-S Hornig B. Vitamins, antioxidants and endothelial function in coronary artery disease. Cardiovasc Drugs Ther. 2002;16(5): Yusoff K. Vitamin E in cardiovascular disease: has the die been cast? Asia Pac J Clin Nutr. 2002;11(suppl 7):S443-S Hamabe A, Takase B, Uehata A, Kurita A, Ohsuzu F, Tamai S. Impaired endothelium-dependent vasodilation in the brachial artery in variant angina pectoris and the effect of intravenous administration of vitamin C. Am J Cardiol. 2001;87(10): Riemersma RA, Carruthers KF, Elton RA, Fox KA. Vitamin C and the risk of acute myocardial infarction. Am J Clin Nutr. 2000;71(5): Wolff AA. The MARISA Investigators. MARISA: monotherapy assessment of ranolazine in stable angina. J Am Coll Cardiol. 2000;35(suppl A):408A. 23. Chaitman BR, Pepine CJ, Parker JO, et al, for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3): Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischaemia during daily life. The Atenolol Silent Ischaemia Study (ASIST). Circulation. 1994;90(2): Boden WE, Bough EW, Reichman MJ, et al. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on beta-blockers and nitrates: a randomized, double-blind, placebo-controlled cross-over study. Circulation. 1985;71(6): Davies RF, Habibi H, Klinke WP, et al. for the Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. J Am Coll Cardiol. 1995;25(3): Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet. 1991;338(8774): Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, for the TIBET Study Group. The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J. 1996;17(1): Hung J, Lamb IH, Connolly SJ, Jutzy KR, Goris ML, Schroeder JS. The effect of diltiazem and propranolol, alone and in combination, on exercise performance and left ventricular function in patients with stable effort angina: a double-blind, randomized, and placebo-controlled study. Circulation. 1983;68(3): Packer M. Drug therapy: combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med. 1989;320(11): Pehrsson SK, Ringqvist I, Ekdahl S, Karlson BW, Ulvenstam G, Persson S. Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris. Clin Cardiol. 2000;23(10): Berger P. Ranolazine and other antianginal therapies in the era of the drug-eluting stent. JAMA. 2004;291(3): S478 Vol. 4 (6B) June 2004
Emerging Drug List RANOLAZINE
Generic (Trade Name): Manufacturer: Indication: Ranolazine (Ranexa TM ) CV Therapeutics, Inc. For the treatment of stable angina. 1 NO. 58 MAY 2004 Current Regulatory Status: Description: The US Food and
More informationAngina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room
Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University
More informationPharmacology. Drugs affecting the Cardiovascular system (Antianginal Drugs)
Lecture 7 (year3) Dr Noor Al-Hasani Pharmacology University of Baghdad College of dentistry Drugs affecting the Cardiovascular system (Antianginal Drugs) Atherosclerotic disease of the coronary arteries,
More informationChapter (9) Calcium Antagonists
Chapter (9) Calcium Antagonists (CALCIUM CHANNEL BLOCKERS) Classification Mechanism of Anti-ischemic Actions Indications Drug Interaction with Verapamil Contraindications Adverse Effects Treatment of Drug
More informationMore than 64 million Americans have
CLINICAL IMPLICATIONS: A REVIEW OF THE DATA Michael Sack, MD, PhD* ABSTRACT Despite treatment with traditional pharmacotherapy and/or revascularization, angina remains a significant health problem for
More informationThe rationale of metabolic treatment in ischaemic heart disease
Invited review The rationale of metabolic treatment in ischaemic heart disease Mario Marzilli 1, Marta Focardi 2, Silvia Affinito 2, Eugenia Capati 2, Rossella Urselli 2 1Division of Cardiovascular Medicine,
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationRanolazine: An Update
Ranolazine: An Update J. Dawn Abbott, M.D., F.A.C.C., F.S.C.A.I. Director, Interventional Cardiology Fellowship Associate Professor of Medicine Brown Medical School Cardiovascular Institute Outline Ranolazine
More informationANGINA PECTORIS. angina pectoris is a symptom of myocardial ischemia in the absence of infarction
Pharmacology Ezra Levy, Pharm.D. ANGINA PECTORIS A. Definition angina pectoris is a symptom of myocardial ischemia in the absence of infarction angina usually implies severe chest pain or discomfort during
More informationMain clinical article. Persistent angina
Mario Marzilli, Marta Focardi, Silvia Affinito, Eugenia Capati and Rossella Urselli Postgraduate School of Cardiology, University of Siena, Italy Correspondence: Dr M. Marzilli, Postgraduate School of
More informationAngina Pectoris Dr. Shariq Syed
Angina Pectoris Dr. Syed 1 What is Angina Pectoris (AP)? Commonly known as angina is chest pain often due to ischemia of the heart muscle, Because of obstruction or spasm of the coronary arteries 2 What
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationRomualdo Belardinelli, MD, FESC Cardiovascular Sciences Department, Lancisi Heart Institute, AOR Ancona, Italy
Original Article Heart Metab. (2017) 73:13-17 Treating myocardial ischemia in diabetics: drugs, surgery, and stents Romualdo Belardinelli, MD, FESC Cardiovascular Sciences Department, Lancisi Heart Institute,
More informationTreatment of T Angina reatment of By Ali Alalawi
Treatment of Angina By Ali Alalawi Determinants of Oxygen Demand Need to improve ratio of: Coronary blood flow / cardiac work Or Cardiac O2 Supply / Cardiac Requirement Coronary Circulation vs Other Circulation
More informationScreening for Asymptomatic Coronary Artery Disease: When, How, and Why?
Screening for Asymptomatic Coronary Artery Disease: When, How, and Why? Joseph S. Terlato, MD FACC Clinical Assistant Professor, Brown Medical School Coastal Medical Definition The presence of objective
More informationDRUGS USED IN ANGINA PECTORIS
DRUGS USED IN ANGINA PECTORIS Course: Integrated Therapeutics 1 Lecturer: Dr. E. Konorev Date: November 16, 2010 Materials on: Exam #7 Required reading: Katzung, Chapter 12 1 TYPES OF ISCHEMIC HEART DISEASE
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL
2 nd Re-Submission ranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL 09 December 2011 The Scottish Medicines Consortium (SMC) has completed
More informationTreatment of Stable Coronary Artery Disease Pharmacotherapy
Treatment of Stable Coronary Artery Disease Pharmacotherapy José López-Sendón Hospital Universitario La Paz. Madrid. Spain Conflict of interest: I will discuss off label use and/or investigational use
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationClinical benefits of trimetazidine in diabetic patients with coronary artery disease
Clinical benefits of trimetazidine in diabetic patients with coronary artery disease Department of Cardiology, Ain Shams University, Cairo, Egypt Correspondence:, Department of Cardiology, Ain Shams University,
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationManaging IHD and acute Myocardial Infarction
Managing IHD and acute Myocardial Infarction In Ireland- 1 out of every 10 deaths ( 22% of all premature deaths) in 2006 were due to CVD 30,000 15,000 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 Source
More informationObjectives. Pharmacological Management of Chronic Coronary Artery Disease. Epidemiology
Pharmacological Management of Chronic Coronary Artery Disease Objectives Review the principles of myocardial oxygen supply and demand Review the mechanism of action, adverse effects, and clinical use of
More informationManagement of the coronary patient in Roberto Ferrari
Management of the coronary patient in 2011 Roberto Ferrari What is new in treatment of stable CAD? In the era of interventional cardiology, is chronic stable angina a rare disease? Stable angina pectoris
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationMedical Biochemistry and Molecular Biology department
Medical Biochemistry and Molecular Biology department Cardiac Fuels [Sources of energy for the Cardiac muscle] Intended learning outcomes of the lecture: By the end of this lecture you would be able to:-
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationIndependent Review Panel (IRP)
Independent Review Panel (IRP) ranolazine, 375mg, 500mg and 750mg prolonged-release tablets (Ranexa ) SMC No. (565/09) A. Menarini Pharma UK SRL 05 October 2012 The Scottish Medicines Consortium (SMC)
More informationAntianginal Drugs 18 I. OVERVIEW II. TYPES OF ANGINA
Antianginal Drugs 18 I. OVERVIEW Atherosclerotic disease of the coronary arteries, also known as coronary artery disease or ischemic heart disease, is the most common cause of mortality around the world.
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationAnginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial
Angina Anginal pain is a result of an imbalance between myocardial oxygen supply and demand. Pharmacological management is aimed at prevention of myocardial ischemia and pain as well as prevention of myocardial
More informationCardiovascular drugs
chapter 13 Cardiovascular drugs Cardiovascular drugs act on the heart or blood vessels to control the cardiovascular system. They are used to treat a variety of conditions from hypertension to chronic
More informationMedicine Dr. Omed Lecture 2 Stable and Unstable Angina
Medicine Dr. Omed Lecture 2 Stable and Unstable Angina Risk stratification in stable angina. High Risk; *post infarct angina, *poor effort tolerance, *ischemia at low workload, *left main or three vessel
More informationAbbreviated New Drug Evaluation: Ranolazine
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationShort Communication Effect of Atorvastatin on E.C.G changes in Coronary artery disease Singh H 1, Gupta A 2, Bajaj VK 3, Gill BS 4, Singh J 5
Short Communication Effect of Atorvastatin on E.C.G changes in Coronary artery disease Singh H 1, Gupta A 2, Bajaj VK 3, Gill BS 4, Singh J 5 1 Dr. Harmanjit Singh Senior resident, Pharmacology PGIMER,
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationRANOLAZINE AND IVABRADINE - THEIR CURRENT USE
3 : 35 RANOLAZINE AND IVABRADINE - THEIR CURRENT USE Abstract Chronic stable angina is a debilitating illness affecting millions worldwide. Considerable progress has been made over the last 30 years in
More informationManagement of Stable Angina Drugs, Stents and Devices for Coronary Bypass Surgery
Management of Stable Angina Drugs, Stents and Devices for Coronary Bypass Surgery a report by Udho Thadani Professor of Medicine, Division of Cardiology, Oklahoma University Health Sciences Center (OUHSC)
More informationEfficacy of Ranolazine in Patients With Chronic Angina
Journal of the American College of Cardiology Vol. 53, No. 17, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.01.037
More informationDrug Treatment of Ischemic Heart Disease
Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE School of Medicine, The University of Jordan November, 2017 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant
More informationPharmacotherapy of Angina Pectoris
Pharmacotherapy of Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth
More informationInitial Medical and Surgical Management of Unstable Angina Pectoris
Clin. Cardiol. 2. 311-316 (I979) G. Witzstrock Publishing House. Inc. Editorial Initial Medical and Surgical Management of Unstable Angina Pectoris Introduction The purpose of this report is to review
More informationPharmacotherapy of Angina Pectoris
Pharmacotherapy of Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth
More informationDrug Treatment of Ischemic Heart Disease
Drug Treatment of Ischemic Heart Disease Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine, The University of Jordan November, 2014 Categories of Ischemic Heart Disease Fixed "Stable, Effort Angina Variant
More informationCurrent Nonpharmacologic Management of Coronary Artery Disease: Focus on External Counterpulsation C. Richard Conti, MD, MACC
Current Nonpharmacologic Management of Coronary Artery Disease: Focus on External Counterpulsation C. Richard Conti, MD, MACC Address Department of Medicine, University of Florida College of Medicine,
More informationChanges in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy
European Heart Journal Supplements (2001) 3 (Supplement O), O2 O7 Changes in cardiac metabolism: a critical step from stable angina to ischaemic cardiomyopathy W. C. Stanley Department of Physiology and
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationStable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology
Stable Ischemic Heart Disease Ivan Anderson, MD RIHVH Cardiology Outline Review of the vascular biology of atherosclerosis Why not just cath everyone with angina? Medical management of ischemic cardiomyopathy
More informationUtility of ranolazine in chronic stable angina patients
REVIEW Utility of ranolazine in chronic stable angina patients Pawan D Patel Rohit R Arora Department of Cardiology, Chicago Medical School, North Chicago, IL, USA Abstract: Chronic stable angina is a
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationMonth/Year of Review: November 2014 Date of Last Review: June 2012 PDL Classes: Anti-anginals, Cardiovascular
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationA Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive protein In Cardiac Patients
Human Journals Mini Review March 2017 Vol.:8, Issue: 4 All rights are reserved by Prof. Dr. Mathew George et al. A Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationfunction in patients with ischaemic heart disease
Br. J. clin. Pharmac. (1986), 22, 319S-324S Calcium antagonist treatment and its effects on left ventricular function in patients with ischaemic heart disease E. A. RODRIGUES, I. M. AL-KHAWAJA, A. LAHIRI
More informationClinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126
Stable angina: management Clinical guideline Published: 23 July 2011 nice.org.uk/guidance/cg126 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAntianginal Drugs. Garrett J. Gross THE THERAPEUTIC OBJECTIVES IN THE USE OF ANTIANGINAL DRUGS
17 Antianginal Drugs Garrett J. Gross DRUG LIST GENERIC NAME PAGE GENERIC NAME PAGE Atenolol 201 Diltiazem 203 Isosorbide dinitrate 197 Isosorbide mononitrate 197 Metoprolol 201 Nadolol 201 Nitroglycerin
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationChronic stable angina pectoris can manifest as predictable and reproducible. Chronic Angina: New Medical Options for Treatment CME-CERTIFIED ARTICLE
CME-CERTIFIED ARTICLE TREATMENT UPDATE Chronic Angina: New Medical Options for Treatment Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Department of Medicine, Divisions of Cardiology, Nutrition
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationAngina and left ventricular dysfunction
European Heart Journal (1996) 17 {Supplement G), 2-7 Angina and left ventricular dysfunction H. J. Dargie From the CRI in Heart Failure, University of Glasgow, Glasgow, U. K. Angina with left ventricular
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More informationHow to successfully manage patients with ischemic heart disease
Cardiology Update 2013 Satellite symposium A. Menarini Davos, February 14, 2013 How to successfully manage patients with ischemic heart disease François Mach Cardiology Department Geneva University Hospital
More informationOff-Label Disclaimer
Off-Label Disclaimer Slides that include contain data that is not within the FDA approved package insert and have not otherwise been approved by the FDA 1 ASSESSMENT AND TREATMENT GOALS OF CHRONIC ANGINA
More informationThe number of patients being treated for angina in the
Vol 4 January 2012 Clinical Pharmacist 13 Management of stable angina involves symptomatic relief of chest pain, longer-acting control of symptoms and prevention of cardiovascular complications. This article
More informationHeart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United
Heart disease remains the leading cause of morbidity and mortality in industrialized nations. It accounts for nearly 40% of all deaths in the United States, totaling about 750,000 individuals annually
More informationAngina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.
Lonet Tablet Description Lonet contains Atenolol, a synthetic β1 selective (cardioselective) adrenoreceptor blocking agent without membrane stabilising or intrinsic sympathomimetic (partial agonist) activity.
More informationVALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION
VALUE OF ACEI IN THE MANAGEMENT OF HYPERTENSION Dr Catherine BESEME Paris 6 th December 2005 6 th International Congress of Bangladesh Society of Medicine Hypertension is a risk factor at the source, with
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More informationCIGNA PHARMACY COVERAGE POLICY
CIGNA PHARMACY COVERAGE POLICY The following Coverage Policy applies to all plans administered by CIGNA Companies including plans administered by Great-West Healthcare, which is now a part of CIGNA. Subject
More informationTerm-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY
MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple
More informationMETOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets
METOTRUST XL-25/50 Metoprolol Succinate Extended-Release Tablets COMPOSITION Each film-coated tablet of Metotrust XL-25 contains: Metoprolol Succinate USP 23.75 mg equivalent to Metoprolol Tartrate 25
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationIschemic Heart Disease
Ischemic Heart Disease Definition: Ischemic heart disease (IHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium; it typically occurs when there
More informationIschaemic heart disease. IInd Chair and Clinic of Cardiology
Ischaemic heart disease IInd Chair and Clinic of Cardiology Definition Syndrome due to chronic insufficient oxygen supply to myocardial cells Nomenclature: ischaemic heart disease (IHD), coronary artery
More informationManagement of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
More informationChapter 9. Learning Objectives. Learning Objectives 9/11/2012. Cardiac Arrhythmias. Define electrical therapy
Chapter 9 Cardiac Arrhythmias Learning Objectives Define electrical therapy Explain why electrical therapy is preferred initial therapy over drug administration for cardiac arrest and some arrhythmias
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationClinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases
Cardiol Ther (2016) 5:75 82 DOI 10.1007/s40119-016-0059-1 ORIGINAL RESEARCH Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases Luis Rodríguez Padial. Gonzalo Barón-Esquivias.
More informationThe Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction
The Beneficial Role of Angiotensin- Converting Enzyme Inhibitor in Acute Myocardial Infarction Cardiovascular Center, Korea University Guro Hospital 2007. 4. 20 Seung-Woon Rha, MD, PhD Introduction 1.
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationSecond Generation of Calcium Antagonists
Winifred G. Nayler Second Generation of Calcium Antagonists With 81 Figures and 63 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Hong Kong Barcelona Budapest Contents Foreword Chapter
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationPyruvate + NADH + H + ==== Lactate + NAD +
1 UNIVERSITY OF PAPUA NEW GUINEA SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY PBL SEMINAR ANAEROBIC METABOLISM - An Overview
More information